Abstract: A process for preparing compounds of the formula I ##STR1## wherein either (i) each of R.sub.1 and R.sub.2 independently represents H or an organic group, or (ii) NR.sub.1 R.sub.2 is a heterocyclic ring or (iii) R.sub.2 is H and R.sub.1 is ##STR2## wherein each of R.sub.6 and R.sub.7 independently represents H or an organic group, m is 1 or 2, n is 0-3, X is O, S, NH, NR.sub.8, CHNO.sub.2 or CHSO.sub.2 R.sub.4 wherein R.sub.8 and R.sub.4 are organic groups and R.sub.3 represents an organic group is characterized by the following reaction sequence: ##STR3## There are also provided new compounds of the formula I wherein n is 0 and m is 2 and pharmaceutical compositions containing them. These compounds and their pharmaceutically acceptable acid addition salts are active as anti-ulcer agents.

Abstract: A compound of formula I: ##STR1## wherein either (i) each of R.sub.1 and R.sub.2 independently represents a hydrogen atom or an organic group, or (ii) R.sub.1 and R.sub.2 linked together form a heterocyclic ring or (iii) R.sub.2 is hydrogen and R.sub.1 is ##STR2## wherein each of R.sub.6 and R.sub.7 independently represents hydrogen or an organic group, n is 0-3, X is O, S, NH, NR.sub.8, CHNO.sub.2 or CHSO.sub.2 R.sub.4, wherein R.sub.8 and R.sub.4 are organic groups and R.sub.3 represents an organic group. The compound of formula I is effective as an anti-ulcer agent and is highly effective as a histamine H.sub.2 -receptor antagonist.

Abstract: Compounds are disclosed of the general formula (I): ##STR1## wherein R.sub.1 is a lower alkyl having from 1 to 4 carbon atoms; R.sub.2 is hydrogen or a lower alkyl having from 1 to 4 carbon atoms; and R.sub.3 is a saturated or unsaturated straight or branched alkyl having from 1 to 4 carbon atoms. A process for making such compounds is also disclosed. These compounds are useful as antiulcer agents and as inhibitors of gastric secretion.

Abstract: New 4,5,6,7-tetrahydroimidazo-[4,5-c]-pyridine derivatives are disclosed, and more particularly derivatives of Formula I ##STR1## where R.sub.1 is hydrogen or an alkyl having from 1 to 4 carbon atoms;R.sub.2 is hydrogen, an alkyl having from 1 to 4 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, phenyl or a heterocycle;R.sub.3 is hydrogen, a saturated or unsaturated straight or branched alkyl having from 1 to 6 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, benzoyl or phenyl; andX is O, S or NR.sub.4 where R.sub.4 is hydrogen, an alkyl having from 1 to 4 carbon atoms, cyano, amino, nitro or acylamino;Or pharmaceutically acceptable acid addition salts thereof.

Abstract: A process for the preparation of azetidinone-thiazoline precursors for cephalosporin synthesis.

Abstract: New derivatives of caffeine are disclosed having the formula: ##SPC1##Where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are selected from the group consisting of hydrogen, chlorine, bromine, an alkyl or an alkoxy radical containing from 1 to 4 carbon atoms. They are made by transforming 8-.alpha. hydroxyethyl caffeine into the corresponding 8-.alpha.-chloroethyl caffeine by the action of a suitable chlorinating agent such as thionyl chloride, reacting the product so obtained in a suitable solvent such as anhydrous dimethylformamide at a temperature from 40.degree. to 110.degree. C and for a period of time from 1 to 5 hours with the sodium or potassium salt of a nicotinic acid of the formula: ##SPC2##Where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the above-mentioned meanings, and crystallizing the resulting product from a suitable solvent, such as ethanol. These new compounds have broncholitic activity.